CSRidentity
 
 
Our plan : In 2016-18, we plan to share issue programmes of governments, corporates, NGOs, FAs... in any country with focus on Thane, other districts of India.
Our vision : Universal development Our mission : Be sustainable, promote others Our focus : Share challenges & solutions email your programmes on issues
HIV/AIDS programmes HIV/AIDS : Funding proposals by various stakeholders

HIV/AIDS
We share the status of HIV/AIDS in many countries and would soon interview experts to share the real challenges of HIV/AIDS.

We are covering how each subissue of HIV/AIDS is handled with programmes by all stakeholders like NGOs, corporates, funding agencies, philanthropists.

We plan to cover HIV or HIV-AIDS as a separate issue and not a subissue of health because it is not just a health issue but it has effect on the entire family or entire communities and this effect is not just of health but of economy. And this economy is not just family economy but national economy.

HIV and AIDS affects economic growth by reducing the availability of human capital. Without proper prevention, nutrition, health care and medicine that is available in developing countries, large numbers of people are falling victim to AIDS.

People living with HIV/AIDS will not only be unable to work, but will also require significant medical care. The forecast is that this will probably cause a collapse of economies and societies in countries with a significant AIDS population. In some heavily infected areas, the epidemic has left behind many orphans cared for by elderly grandparents.

The increased mortality in this region will result in a smaller skilled population and labor force. This smaller labor force will be predominantly young people, with reduced knowledge and work experience leading to reduced productivity. An increase in workers’ time off to look after sick family members or for sick leave will also lower productivity. Increased mortality will also weaken the mechanisms that generate human capital and investment in people, through loss of income and the death of parents. As the epidemic progresses, the age profile of those infected will increase, though the peak is expected to stay within the working age population. HIV disproportionately infects and impacts on women, so those sectors employing large numbers of women e.g. education, may be disproportionately economically impacted by HIV

Apollo Tyres Ltd.

HIV-AIDS
The company’s HIV-AIDS Awareness and Prevention Programme is targeted at 4 key stakeholders — employees, customers, business partners and community. Under this, Apollo undertakes awareness and prevention sessions and provides voluntary, confidential testing and support.

The Programme has the largest footprint in India and South Africa. At both locations, formally trained Master Trainers — from amongst the employees — conduct awareness modules for their colleagues as well as for the company’s business partners.

In India, the company runs 21 Health Care Centres in prominent transhipment hubs for the commercial vehicle community. Each of these centres is equipped with qualified doctors, paramedic staff and counsellors, and also has its own network of peer educators who work with the community to effect behaviour change.

Source

More programmes of various stakeholders are accessible to content members.

Bajaj Auto

Bajaj - YCM Hospital A.R.T. Centre for HIV/Aids - Pimpri
Government of India - Ministry of Health and Family Welfare - National Aids Control Organisation (NACO) and CII have initiated Public Private Partnership (PPP) in order to provide better healthcare to Aids patients. Your company has signed a tripartite MOU with NACO and Yeshwantrao Chavan Municipal Hospital (YCMH) in Pimpri to set up an Anti Retroviral Treatment Centre (ART Centre) at YCMH in Pimpri, Pune with the cooperation of Pimpri Chinchwad Municipal Corporation for HIV patients.
Many dignitaries from Global Fund, WHO and such other organizations have visited the ART centre, which is the largest unit run by an industry under Public Private Partnership program. Apart from two doctors and six supporting medical staff, the ART centre has added audio-visual facilities for group counseling, as a result of which the ART centre registration has reached 3900 patients and the unit is recognized today as one of the best ART centers in the country.

Source

More programmes of various stakeholders are accessible to content members.

Ballarpur Industries Ltd.

BILT runs two ART centres in high prevalence but resource poor districts in the states of Odisha and Maharashtra. The Centres are based on a Public Private Partnership (PPP) model in collaboration with National AIDS Control Organization, (NACO) New Delhi with technical support from Confederation of Indian Industries, New Delhi. Today, the centre reaches out to more than 2329 PLHIV patients out of which 1193 are on ART drugs. Majority of the patients registered at the centre are poor and have no access to resources. The early experience showed that in spite of the patients being on ART their health status was not improving as expected.

The project provides an integrated package of support services to PLHA registered with the ART centres and their families. This includes nutritional counselling and support, income generation training and support, reduction of stigma and discrimination. The change in the quality of life is reflected in indicators like weight gain, CD4 count (marker indicator), Hb. Percentage, and so on. This is the first such project in the country which directly works with the patients who are on ART. The project has two components - clinical and outreach. The clinical team provides treatment and monitors the patients with regard to clinical aspects, while the outreach team visit the families, provides home based care, nutritional and other counselling. The project is committed to providing complete confidentiality and has written consent of each patient for

Source

More programmes of various stakeholders are accessible to content members.

Cipla Ltd.

HIV/ AIDs

A commitment beyond compare
In the early 1990s, India witnessed an alarming increase in the number of AIDS cases. We launched Zidovudine, an antiretroviral at 1/10th of the price available in international markets. Subsequently Lamivudine and Stavudine were launched.

Nevirapine was launched in 2000 and this completed the availability of triple therapy manufactured in India.

In 2001,we developed the world’s first 3-in-1 recommended fixed dose combination (Stavudine + Lamivudine + Nevirapine) to fight HIV/ AIDS. This amazing breakthrough overcame many challenges: it ensured adherence, lessened pill burden and it was affordable and available to all at less than a ‘Dollar a Day’. It was the first anti-AIDS cocktail that brought the cost of treatment down from $12,000 per patient per year to around $300. Enabling millions across the developing world access to life-saving therapy.

We have pioneered the development of child-friendly, 3-in-1 pediatric formulations like dispersible fixed-dose combinations for babies and children with HIV/ AIDS.

We launched a first-of-its-kind ‘Mother-Baby Pack’ containing an entire range of antiretroviral drugs to prevent mother to child transmission of HIV/ AIDS.

We have 7 world firsts for adults and 5 for children.

We have the world’s widest range of antiretroviral products approved by WHO, US FDA…

25 of our antiretrovirals are approved under PEPFAR and pre-qualified by WHO.

We make 16 antiretroviral drugs for first line, second line and third line. And over 40 different packs: 2-in-1 Fixed Dose Combinations, 3-in-1 Fixed Dose Combinations / kits and liquids. Today our range covers about 70-80% of available anti-AIDS drugs.

We have created awareness about Post Exposure Prophylaxis (PEP) for healthcare workers.

Our antiretrovirals are supplied to more than 115 countries and various Ministries of Health worldwide, including the Government of India and international aid agencies like UNICEF, UNITAID, Clinton Foundation, MSF, IDA, PAHO...

Our fight against HIV/ AIDS has increased accessibility worldwide. And with our continued commitment to research and development the world can look forward to further progress in our fight against HIV/ AIDS.

Source

More programmes of various stakeholders are accessible to content members.

 

Untitled Document